Researchers have uncovered a novel method of overriding the growth promoting effects of PTEN deletion and the answer is to inhibit another tumor suppressor gene.
This meta-analysis evaluates the association between Notch1 and cervical cancer, drawing conclusions regarding Notch1 expression and aggressive biological behaviors within the disease.
Study determines that there are two distinct routes to HER2 activation within lung cancer, suggesting that HER2-related lung cancers may be two related but separate diseases.
Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients
This study presents results of miR-331 expression in acute myeloid leukemia patients and its effect on patients’ clinical outcome.
Researchers from The Scripps Research Institute (FL, USA) have discovered a new synthetic compound that inhibits a protein known to play a key role in breast and pancreatic cancer progression.
Investigation determines role of hTERT promoter mutations present in >75% of glioblastomas and melanomas
An investigation carried out by researchers at the University of Louisville’s James Graham Brown Cancer Center (KY, USA) has defined the role of destabilizing mutations in the hTERT gene promoter that are detectable in >75% of glioblastomas and melanomas.
Researchers from the Johns Hopkins Kimmel Cancer Center (MD, USA) have identified a gene that may help to explain why some breast cancers are resistant to tamoxifen, a hormone treatment generally used after surgery, radiation and other chemotherapy.
A study presented at the 2014 European Society for Medical Oncology (ESMO) Congress (26–30 September, Madrid, Spain) has measured expression levels of an enzyme involved in DNA synthesis, allowing prediction of chemotherapy response in lung cancers.
A potentially important discovery has been made during ongoing investigations in the laboratory of Kristi Neufeld at the University of Kansas Cancer Center (KS, USA).
A recent study, the results of which were published by Nature’s Scientific Reports , investigated the role of human epididymis protein 4 (HE4) in modulating response to hormones and hormonal therapies in ovarian cancer.